Your Patients Need Revumenib — Here's How to Get It to Them

As a prescriber, you know the clinical value of Revumenib (brand name Revuforj) for patients with relapsed or refractory acute leukemia harboring KMT2A translocations or NPM1 mutations. But you also know that prescribing it is only half the battle. The other half — actually getting the drug into your patient's hands — requires navigating a specialty distribution system that can frustrate even experienced practices.

This guide provides a practical, step-by-step framework for helping your patients find and access Revumenib in 2026.

Current Availability

Revumenib is not in formal shortage as of early 2026 per FDA and ASHP databases. However, its availability is limited to specialty pharmacies, and several factors create access delays:

• Exclusive specialty pharmacy distribution — not available at retail chains
• Prior authorization required by most payers
• Genetic testing confirmation needed (KMT2A translocation or NPM1 mutation)
• High WAC (~$39,500/month) may trigger additional utilization management
• Expanded NPM1 indication (October 2025) has increased the eligible patient pool

Why Your Patients Can't Find Revumenib

From the patient perspective, the access barriers are significant:

They Don't Know About Specialty Pharmacies

Many patients have never dealt with a specialty medication before. They may try to fill the prescription at their local pharmacy and be told it's not available — without understanding why or what to do next.

Prior Authorization Takes Time

Even with clear clinical indication, prior authorization can take days to weeks. Patients with aggressive disease don't always have that kind of time.

Cost Shock

When patients learn the drug costs approximately $474,000 per year, they may assume they can't afford it — even when copay assistance programs could reduce their out-of-pocket cost to $0. Without proactive education from their care team, many patients don't know these programs exist.

Information Overload

Patients dealing with a new leukemia diagnosis (or relapse) are already overwhelmed. Adding the complexity of specialty pharmacy navigation, insurance appeals, and financial assistance paperwork can feel insurmountable.

What Providers Can Do: 5 Steps

Step 1: Start Prior Authorization at the Time of Prescribing

Don't wait. Submit the prior authorization the same day you write the prescription. Include:

• FDA-authorized test results confirming KMT2A translocation or NPM1 mutation
• Documentation of relapsed or refractory disease
• For NPM1 indication: documentation that no satisfactory alternatives exist
• Current WBC count (must be <25 Gi/L before initiation)

If your practice has a dedicated prior authorization team, loop them in immediately. Early submission can save days.

Step 2: Enroll Patients in SyndAccess

SyndAccess is Syndax Pharmaceuticals' patient support program. It provides:

• Insurance verification and prior authorization assistance
• Specialty pharmacy coordination to identify pharmacies with stock
• Copay support — eligible commercially insured patients may pay $0 (no income restrictions)
• Financial assistance for patients who need additional help
• Nurse navigator support for patients and caregivers

Enroll patients via the SyndAccess enrollment form at revuforjhcp.com or by calling 1-888-567-SYND (7963).

Step 3: Use Medfinder to Check Real-Time Availability

Medfinder for Providers lets you search for specialty pharmacies that have Revumenib in stock. Rather than calling multiple pharmacies, you can check availability in one place and direct your patient (or your pharmacy coordinator) to the right location.

This is especially useful when a patient's usual specialty pharmacy has a backorder or when you need to find an alternative dispensing location quickly.

Step 4: Educate Patients About Cost Assistance

Many patients assume they can't afford Revumenib when they see the price. Be proactive about discussing:

• The Revuforj Copay Program — $0 copay for eligible commercially insured patients
• SyndAccess financial assistance for uninsured or underinsured patients
• The fact that Medicare and Medicaid patients have separate coverage pathways (though the copay program does not apply to government insurance)

Having a printed handout or directing patients to our patient guide on saving money on Revumenib can help reinforce this information after the appointment.

Step 5: Follow Up Within the First Week

Check in with your patient (or have your care coordinator check in) within 5-7 days of prescribing to ensure:

• Prior authorization has been submitted and is moving forward
• SyndAccess enrollment is complete
• A specialty pharmacy has been identified and has received the prescription
• The patient understands the expected timeline for receiving their medication

Early intervention when problems arise can prevent gaps in treatment.

Alternatives When Access Is Delayed

If Revumenib access is delayed, consider:

• Bridge therapy — Hypomethylating agents with or without Venetoclax while awaiting Revumenib
• Clinical trial enrollment — Other menin inhibitors (Ziftomenib, Bleximenib, Enzomenib) are in late-stage trials
• Emergency or compassionate use — Contact Syndax Pharmaceuticals directly to discuss options for urgent cases

For a patient-facing overview of alternatives, see: Alternatives to Revumenib.

Workflow Tips for Your Practice

• Designate a point person — Assign a team member to manage Revumenib access for all patients. This creates institutional knowledge and speeds up the process over time.
• Create a checklist — Build a standard checklist for Revumenib prescribing: genetic test confirmation, WBC check, prior auth submission, SyndAccess enrollment, specialty pharmacy contact, and patient follow-up.
• Bookmark key resources — Keep Medfinder, the SyndAccess enrollment portal, and the Revuforj prescribing information easily accessible for your team.
• Document everything — Keep records of all prior authorization submissions, appeals, and pharmacy communications. This speeds up future prescriptions and helps with appeals.
• Coordinate with your hospital pharmacy — If you're in an academic or hospital setting, your institutional pharmacy may have established relationships with the specialty pharmacy network and can facilitate faster access.

Final Thoughts

Revumenib is a first-in-class treatment that can make a meaningful difference for patients with KMT2A-rearranged or NPM1-mutated acute leukemia. The access challenges are real but manageable with a systematic approach.

By starting prior authorization early, enrolling patients in SyndAccess, leveraging tools like Medfinder, educating patients about cost assistance, and following up proactively, you can significantly reduce the time it takes to get this critical medication to the patients who need it.

For the latest on Revumenib availability and the menin inhibitor landscape, see our provider-focused update: Revumenib shortage: What providers need to know in 2026.